Brief: Lantheus Announces US FDA Approval Of DEFINITY For Pediatric Patients
04/03/2024 14:56
March 4 (Reuters) - Lantheus Holdings Inc LNTH.O :
* LANTHEUS ANNOUNCES THE FDA APPROVAL OF DEFINITY®
(PERFLUTREN
LIPID MICROSPHERE) FOR PEDIATRIC PATIENTS
Source text for Eikon: ID:nGNX3qtVqh
Further company coverage: LNTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsStreet View: Lantheus' tumor kit setback seen as temporary, with growth catalysts still ahead
Brief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say